TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer

Cited by papers we hold 13

• Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies · 2022
  No notice
• CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer · 2021
  No notice
• Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes · 2021
  No notice
• Classification of triple-negative breast cancers based on Immunogenomic profiling · 2018
  No notice
• Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy · 2018
  No notice
• Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity · 2017
  No notice
• Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer · 2017
  No notice
• RANKL/RANK control Brca1 mutation-driven mammary tumors · 2016
  No notice
• Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer · 2016
  No notice
• Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection · 2016
  No notice
• Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response · 2015
  No notice
• Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy · 2015
  No notice
• PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.